Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy.
In a big breakthrough for cancer treatment, Dr. Vinod Balachandran, a surgeon-scientist at Memorial Sloan Kettering Cancer ...
Astellas Pharma’s strong pipeline and revenue growth support a positive outlook. See why ALPMF stock is a "Buy," driven by ...
Two years after Neil Armstrong walked on the Moon, US president Richard Nixon declared a new frontier in American scientific ...
Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...
Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...
Researchers from the VIB-KU Leuven Center for Cancer Biology, in collaboration with other scientists, have discovered a way ...
New research shows that fecal transplants may boost the effectiveness of cancer immunotherapy drugs called PD-1 inhibitors.
Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, ...
The NCI will lead the trial of the firm's Versamune MUC1 immunotherapy and its antibody-drug conjugate PDS01ADC.
The Hearty Soul on MSN3d
Rectal Cancer Vanishes After Immunotherapy Trial, Now Classified as FDA Breakthrough TherapyA humble yet groundbreaking clinical trial at Memorial Sloan Kettering Cancer Center (MSK) has achieved unprecedented results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback